In addition, differently from other solid tumors where PD-L1 and TMB seem to be potential predictive biomarkers of the response to ICIs, the results from the phase III trials suggest that neither PD-L1 expression nor TMB appear to be suitable biomarkers able to predict responses to chemoimmunotherapy in SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.